Glaukos Corporation
- GKOS
- NYSE
- Medical devices
- Ophthalmic Medical Devices
- Glaucoma Stents
$166.96
Today +1.29%Quote Oct 19, 2026, 08:00 PM UTC
+1.92%over the last month
Max drawdown −6.3%From 1-month high −3.0%3 months +9.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Glaukos
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W.
Where the money comes from
Q4 2020 revenue $73.2M
- Glaucoma$58.4M79.7%
- Corneal Health$14.9M20.3%
Sector
Healthcare
Industry
Medical devices
Exchange
NYSE
Employees
1,094
Founded
1998
Market value
$9.85B
Quote Oct 19
Floor
$166.41
0.3% below price
Resistance
$166.90
Price is above this level
Price vs analyst targets
25 analysts
Lowest target
$150.00Highest target
$215.00
$150.00Highest target
$215.00
- Price $166.96
- Average target $192.90
- Analysts' target range
Analysts' average target sits about 16% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GKOSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free